This is an open-label study, where participants will be switched from their current HIV medication to the study drug, BIC/F/TAF. Open-label means both the investigator and the participant will know what drug will be given. Participants will be followed for 48 weeks in order to monitor the efficacy, safety and tolerability of BIC/F/TAF. The investigator hypothesizes that BIC/F/TAF will be an important addition to the management of HIV-positive post renal transplant patients, especially since it is a one pill daily dosing regimen, thereby decreasing the pill burden in this population.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Subjects With Plasma HIV-1 Ribonucleic Acid (RNA) <50 Copies/ml
Timeframe: Up to week 48 (End of Study)
Safety (Tolerability) as Measured by the Number of Subjects Who Had a Serious Adverse Event (SAE)
Timeframe: Up to week 48 (End of study)
Intracellular TAF Levels as Measured by Dried Blood Spot
Timeframe: 12 weeks
Intracellular TAF Levels as Measured by Peripheral Blood Mononuclear Cells (PBMCs)
Timeframe: 12 weeks
Renal Function as Measured by Blood Urea Nitrogen (BUN)
Timeframe: 24 weeks, 48 weeks (End of study)
Renal Function as Measured by Creatinine
Timeframe: 24 weeks, 48 weeks (End of study)
Renal Function as Measured by Creatinine Clearance
Timeframe: 24 weeks, 48 weeks (End of study)
Renal Function as Measured by Estimated Glomerular Filtration Rate (eGFR)
Timeframe: 24 weeks, 48 weeks (End of study)
Tacrolimus Levels
Timeframe: 12 weeks, 24 weeks, 48 weeks (End of study)